Neuromyelitis Optica Spectrum Disorder Market

Global Neuromyelitis Optica Spectrum Disorder Market Size, Trends & Analysis - Forecasts to 2028 By Treatment (Monoclonal Antibody Drugs, Immunosuppressive Agents, Plasma Exchange Therapy, Others), By Dosage Form (Tablets, Injections, Others), By End-User (Hospitals, Specialty Clinics, Homecare, Others), By Region (North America, Asia Pacific, Central & South America, Europe, Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf
This report was recently updated on May 17 2024 with the latest and most recent market numbers

Global Neuromyelitis Optica Spectrum Disorder Market Size

The global Neuromyelitis Optica Spectrum disorder (NMOSD) market is projected to grow at a CAGR of 6.2% from 2023 to 2028.

Neuromyelitis Optica Spectrum disorder (NMOSD) is an autoimmune disease which is also known as Devic disease and is characterized as a chronic disorder of the brain and spinal cord. NMOSD is the acute inflammation of the optic nerve (optic neuritis, ON) and the spinal cord (myelitis). The presence of immunoglobulin G autoantibodies to aquaporin 4 in the water channel of the central nervous system causes 75% of Neuromyelitis optica spectrum disorder incidents. The symptoms of neuromyelitis optica spectrum disorder depends on the antibodies present in the central nervous system and in some incidents they depend on the neurologic structures of the disease effects, and these symptoms can be periodically progressive and commonly follows a regressive and remitting course. In NMOSD, protein and healthy cells present in the spinal cord and eyes are attacked by the immune system of the body, which causes weakness or paralysis of the arms & legs and vision loss.

The increasing incidence and prevalence of neuromyelitis optica spectrum disorder (NMOSD), increasing investment in rare disease treatment infrastructure, and rising demand for better treatment options for neuromyelitis optica spectrum disorder are expected to propel the growth of the market.

Moreover, the high prevalence of multiple sclerosis (MS), rising demand for innovative drugs including mAbs, and the launch of new products and therapies are expected to support the market in the forecast period.

For the symptomatic treatment, the key players are investing in research and development activities that will provide beneficial opportunities in the treatment space. The innovation of new products and treatment therapies for neuromyelitis optica spectrum disorder (NMOSD) is expected to create opportunities for the market. However, the high cost of treatment, the dearth of skilled professionals, and the lack of healthcare infrastructure in developing economies will slow down the growth of the market.

Genentech's Satralizumab is the humanized antibody developed to target the IL-6 receptor in clinical trials and it is currently under phase III of the clinical trial. Bevacizumab and Alpha1-antitrypsin are the new treatment for the acute phase of NMOSD and it is under progression.  Females affected by neuromyelitis optica spectrum disorder are more as compared to males; 3:1 in MS vs. 9:1 in NMOSD. The elderly and children account for 20% of the cases and the median age of NMOSD is 39 years. The enspryng subcutaneous injection developed by Chugai Pharmaceuticals is the best solution for the treatment of relapses of neuromyelitis optica spectrum disorder (NMOSD) including neuromyelitis Optica (NMO).

global neuromyelitis optica spectrum disorder market

Global Neuromyelitis Optica Spectrum Disorder Market: By Treatment

The monoclonal antibody drugs segment is expected to be the fastest-growing segment in the market from 2023-2028. The increasing efficacy and tolerability of monoclonal antibody drugs are used as emerging treatments for autoimmune diseases including neuromyelitis optica spectrum disorder (NMOSD). Monoclonal antibody drugs such as rituximab, Inebilizumab, Tocilizumab, Satralizumab, and Eculizumab are used to treat neuromyelitis optica spectrum disorder (NMOSD).

The plasma exchange therapy segment holds the largest share of the market. When intravenous corticosteroids are insufficient in acute attacks of neuromyelitis optica spectrum disorders (NMOSD), plasma exchange therapy is used as a rescue therapy. Even though the efficacy of PE has not been quantified but plasma exchange therapy is used as rescue or as first-line therapy and it is an effective therapeutic method in patients during acute attacks of NMOSD.

Global Neuromyelitis Optica Spectrum Disorder Market: By Dosage Form

The injections segment is anticipated to be the fastest-growing segment in the market from 2023-2028. The development of new therapy based on injection dosage are driving the growth of this segment.

The tablets segment holds the largest share of the market. The majority of neuromyelitis optica spectrum disorders (NMOSD) therapies use tablets as dosage form the treatment due to their immediate action during an acute attack.

Global Neuromyelitis Optica Spectrum Disorder Market: By End-User

The specialty clinics segment is anticipated to be the fastest-growing segment in the market from 2023-2028. The availability of specialty clinics for neuromyelitis optica spectrum disorders (NMOSD) treatment is rising due to increasing cases. The hospital segment holds the largest share of the market. The use of new therapies to treat of NMOSD is supporting the growth of this segment.

asia paific neuromyelitis optica spectrum disorder market

Global Neuromyelitis Optica Spectrum Disorder Market: By Region

North America is expected to have the largest share in the global market. This is mainly due to initiatives taken by the public and private organizations to spread awareness about NMOSD, the development of new drugs, and the availability of efficient treatment methods across tier 1 and tier 2 hospitals and healthcare settings.

Asia Pacific is expected to be the fastest growing segment in the global market. The increasing incidences of neuromyelitis optica spectrum disorder and the rising investment strategies in the R&D space by Asian governments for the development of new drugs are driving the growth of the market in this region.

Global Neuromyelitis Optica Spectrum Disorder Market Share and Competitor Analysis

F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi (France), Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Zydus Cadila, Boehringer Ingelheim International GmbH., Apotex Inc., and AstraZeneca among others, are some of the key players in the global neuromyelitis optica spectrum disorder market.

Please note: This is not an exhaustive list of companies profiled in the report.

1          STRATEGIC INSIGHTS ON NEW REVENUE POCKETS

1.1    Strategic Opportunity & Attractiveness Analysis

1.1.1        Hot Revenue Pockets

1.1.2        Market Attractiveness Score

1.1.3        Revenue Impacting Opportunity

1.1.4        High Growing Region/Country

1.1.5        Competitor Analysis

1.1.6        Consumer Analysis

1.2    Global Market Estimates' View

1.3    Strategic Insights across Business Functions

1.3.1        For Chief Executive Officers

1.3.2        For Chief Marketing Officers

1.3.3        For Chief Strategy Officers

1.4    Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into

2          TECHNOLOGICAL TRENDS

2.1   Technological Adoption Rate

2.2   Current Trend Impact Analysis

2.3   Future Trend Impact Analysis

2.4   Data Metrics on Feed Stocks

3          GLOBAL MARKET OUTLOOK

3.1   Market Pyramid Analysis

3.1.1        Introduction

3.1.2        Adjacent Market Opportunities

3.1.3        Ancillary Market Opportunities

3.2   Demand Side Analysis

3.2.1        Market Drivers: Impact Analysis

3.2.2        Market Restraints: Impact Analysis

3.2.3        Market Opportunities: Impact Analysis

3.2.4        Market Challenges: Impact Analysis

3.3   Supply Side Analysis

3.3.1        Porter’s Five Forces Analysis

3.3.1.1 Threat of New Entrants

3.3.1.2 Threat of New Substitutes

3.3.1.3 Bargaining Power of Suppliers

3.3.1.4 Bargaining Power of Buyers

3.3.1.5 Intensity of Competitive Rivalry

3.3.2        SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)

3.3.2.1 Political Landscape

3.3.2.2 Economic Landscape

3.3.2.3 Social Landscape

3.3.2.4 Technology Landscape

3.3.3        Value Chain Analysis

3.3.4        Trend Analysis

3.3.5        Gap Analysis

3.3.6        Cost Analysis

4          GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER MARKET, BY TREATMENT

4.1   Introduction

4.2   Neuromyelitis Optica Spectrum Disorder Market: Treatment Scope Key Takeaways

4.3   Revenue Growth Analysis, 2022 & 2028

4.4   Monoclonal Antibody Drugs

4.4.1        Monoclonal Antibody Drugs Market Estimates and Forecast, 2020-2028 (USD Million)

4.5   Immunosuppressive Agents

4.5.1        Immunosuppressive Agents Market Estimates and Forecast, 2020-2028 (USD Million)

4.6   Plasma Exchange Therapy

4.6.1        Plasma Exchange Therapy Market Estimates and Forecast, 2020-2028 (USD Million)

4.7   Others

4.7.1           Others Market Estimates and Forecast, 2020-2028 (USD Million)

5          GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER MARKET, BY DOSAGE FORM

5.1   Introduction

5.2   Neuromyelitis Optica Spectrum Disorder Market: Dosage Form Scope Key Takeaways

5.3   Revenue Growth Analysis, 2022 & 2028

5.4   Tablets

5.4.1        Tablets Market Estimates and Forecast, 2020-2028 (USD Million)

5.5   Injections

5.5.1        Injections Market Estimates and Forecast, 2020-2028 (USD Million)

5.6   Others

5.6.1        Others Market Estimates and Forecast, 2020-2028 (USD Million)

6          GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER MARKET, BY SALES CHANNEL

6.1   Introduction

6.2   Neuromyelitis Optica Spectrum Disorder Market: End-User Scope Key Takeaways

6.3   Revenue Growth Analysis, 2022 & 2028

6.4   Hospitals

6.4.1        Hospitals Market Estimates and Forecast, 2020-2028 (USD Million)

6.5   Specialty Clinics

6.5.1        Specialty Clinics Market Estimates and Forecast, 2020-2028 (USD Million)

6.6   Homecare

6.6.1        Homecare Market Estimates and Forecast, 2020-2028 (USD Million)

6.7   Others

6.7.1        Others Market Estimates and Forecast, 2020-2028 (USD Million)

7          GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER MARKET, BY REGION

7.1   Introduction

7.2   North America Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.1        By Treatment

7.2.2        By Dosage Form

7.2.3        By End-User

7.2.4        By Country

7.2.4.1     U.S. Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.1.1        By Treatment

7.2.4.1.2        By Dosage Form

7.2.4.1.3        By End-User

7.2.4.2     Canada Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.2.1        By Treatment

7.2.4.2.2        By Dosage Form

7.2.4.2.3        By End-User

7.2.4.3     Mexico Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.3.1        By Treatment

7.2.4.3.2        By Dosage Form

7.2.4.3.3        By End-User

7.3   Europe Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.1        By Treatment

7.3.2        By Dosage Form

7.3.3        By End-User

7.3.4        By Country

7.3.4.1     Germany Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.1.1        By Treatment

7.3.4.1.2        By Dosage Form

7.3.4.1.3        By End-User

7.3.4.2     U.K. Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.2.1        By Treatment

7.3.4.2.2        By Dosage Form

7.3.4.2.3        By End-User

7.3.4.3     France Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.3.1        By Treatment

7.3.4.3.2        By Dosage Form

7.3.4.3.3        By End-User

7.3.4.4     Italy Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.4.1        By Treatment

7.3.4.4.2        By Dosage Form

7.2.4.4.3        By End-User

7.3.4.5     Spain Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.5.1        By Treatment

7.3.4.5.2        By Dosage Form

7.2.4.5.3        By End-User

7.3.4.6     Netherlands Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.6.1        By Treatment

7.3.4.6.2        By Dosage Form

7.2.4.6.3        By End-User

7.3.4.7     Rest of Europe Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.7.1        By Treatment

7.3.4.7.2        By Dosage Form

7.2.4.7.3        By End-User

7.4   Asia Pacific Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.1        By Treatment

7.4.2        By Dosage Form

7.4.3        By End-User

7.4.4        By Country

7.4.4.1     China Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.1.1        By Treatment

7.4.4.1.2        By Dosage Form

7.4.4.1.3        By End-User

7.4.4.2     Japan Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.2.1        By Treatment

7.4.4.2.2        By Dosage Form

7.4.4.2.3        By End-User

7.4.4.3     India Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.3.1        By Treatment

7.4.4.3.2        By Dosage Form

7.4.4.3.3        By End-User

7.4.4.4     South Korea Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.4.1        By Treatment

7.4.4.4.2        By Dosage Form

7.4.4.4.3        By End-User

7.4.4.5     Singapore Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.5.1        By Treatment

7.4.4.5.2        By Dosage Form

7.4.4.5.3        By End-User

7.4.4.6     Malaysia Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.6.1        By Treatment

7.4.4.6.2        By Dosage Form

7.4.4.6.3        By End-User

7.4.4.7     Thailand Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.7.1        By Treatment

7.4.4.7.2        By Dosage Form

7.4.4.7.3        By End-User

7.4.4.8     Indonesia Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.8.1        By Treatment

7.4.4.8.2        By Dosage Form

7.4.4.8.3        By End-User

7.4.4.9     Vietnam Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.9.1        By Treatment

7.4.4.9.2        By Dosage Form

7.4.4.9.3        By End-User

7.4.4.10  Taiwan Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.10.1 By Treatment

7.4.4.10.2 By Dosage Form

7.4.4.10.3 By End-User

7.4.4.11  Rest of Asia Pacific Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.11.1 By Treatment

7.4.4.11.2 By Dosage Form

7.4.4.11.3 By End-User

7.5   Middle East & Africa Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.1        By Treatment

7.5.2        By Dosage Form

7.5.3        By End-User

7.5.4        By Country

7.5.4.1     Saudi Arabia Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.1.1        By Treatment

7.5.4.1.2        By Dosage Form

7.5.4.1.3        By End-User

7.5.4.2     U.A.E. Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.2.1        By Treatment

7.5.4.2.2        By Dosage Form

7.5.4.2.3        By End-User

7.5.4.3     Israel Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.3.1        By Treatment

7.5.4.3.2        By Dosage Form

7.5.4.3.3        By End-User

7.5.4.4     South Africa Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.4.1        By Treatment

7.5.4.4.2        By Dosage Form

7.5.4.4.3        By End-User

7.5.4.5     Rest of Middle East & Africa Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.5.1        By Treatment

7.5.4.5.2        By Dosage Form

7.5.4.5.2        By End-User

7.6   Central & South America Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.6.1        By Treatment

7.6.2        By Dosage Form

7.6.3        By End-User

7.6.4        By Country

7.6.4.1     Brazil Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.6.4.1.1        By Treatment

7.6.4.1.2        By Dosage Form

7.6.4.1.3        By End-User

7.6.4.2     Argentina Eaporative Air Cooler Market Estimates and Forecast, 2020-2028 (USD Million)

7.6.4.2.1        By Treatment

7.6.4.2.2        By Dosage Form

7.6.4.2.3        By End-User

7.6.4.3     Chile Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.6.4.3.1        By Treatment

7.6.4.3.2        By Dosage Form

7.6.4.3.3        By End-User

7.6.4.4     Rest of Central & South America Neuromyelitis Optica Spectrum Disorder Market Estimates and Forecast, 2020-2028 (USD Million)

7.6.4.4.1        By Treatment

7.6.4.4.2        By Dosage Form

7.6.4.4.3        By End-User

8          COMPETITIVE LANDCAPE

8.1   Company Market Share Analysis

8.2   Four Quadrant Positioning Matrix

8.2.1        Market Leaders

8.2.2        Market Visionaries

8.2.3        Market Challengers

8.2.4        Niche Market Players

8.3   Vendor Landscape

8.3.1        North America

8.3.2        Europe

8.3.3        Asia Pacific

8.3.4        Rest of the World

8.4   Company Profiles  

8.4.1        F. Hoffmann-La Roche Ltd.

8.4.1.1 Business Description & Financial Analysis

8.4.1.2 SWOT Analysis

8.4.1.3 Products & Services Offered

8.4.1.4 Strategic Alliances between Business Partners

8.4.2        Mylan N.V.

8.4.2.1 Business Description & Financial Analysis

8.4.2.2 SWOT Analysis

8.4.2.3 Products & Services Offered

8.4.2.4 Strategic Alliances between Business Partners

8.4.3        Teva Pharmaceutical Industries Ltd.

8.4.3.1 Business Description & Financial Analysis

8.4.3.2 SWOT Analysis

8.4.3.3 Products & Services Offered

8.4.3.4 Strategic Alliances between Business Partners

8.4.4        Sanofi (France)

8.4.4.1 Business Description & Financial Analysis

8.4.4.2 SWOT Analysis

8.4.4.3 Products & Services Offered

8.4.4.4 Strategic Alliances between Business Partners

8.4.5        Pfizer Inc.

8.4.5.1 Business Description & Financial Analysis

8.4.5.2 SWOT Analysis

8.4.5.3 Products & Services Offered

8.4.5.4 Strategic Alliances between Business Partners

8.4.6        GLAXOSMITHKLINE PLC

8.4.6.1 Business Description & Financial Analysis

8.4.6.2 SWOT Analysis

8.4.6.3 Products & Services Offered

8.4.6.4 Strategic Alliances between Business Partners

8.4.7        Novartis AG  

8.4.7.1 Business Description & Financial Analysis

8.4.7.2 SWOT Analysis

8.4.7.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.8        Zydus Cadila

8.4.8.1 Business Description & Financial Analysis

8.4.8.2 SWOT Analysis

8.4.8.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.9        Boehringer Ingelheim International GmbH.

8.4.9.1 Business Description & Financial Analysis

8.4.9.2 SWOT Analysis

8.4.9.3 Products & Services Offered

8.4.9.4 Strategic Alliances between Business Partners

8.4.10       Apotex Inc.

8.4.10.1 Business Description & Financial Analysis

8.4.10.2 SWOT Analysis

8.4.10.3 Products & Services Offered

8.4.10.4 Strategic Alliances between Business Partners

8.4.11      Other Companies

8.4.11.1 Business Description & Financial Analysis

8.4.11.2 SWOT Analysis

8.4.11.3 Products & Services Offered

8.4.11.4 Strategic Alliances between Business Partners

9          RESEARCH METHODOLOGY

9.1   Market Introduction

9.1.1        Market Definition

9.1.2        Market Scope & Segmentation

9.2   Information Procurement

9.2.1        Secondary Research

9.2.1.1 Purchased Databases

9.2.1.2 GMEs Internal Data Repository

9.2.1.3 Secondary Resources & Third Party Perspectives

9.2.1.4 Company Information Sources

9.2.2        Primary Research

9.2.2.1 Various Dosage Form of Respondents for Primary Interviews

9.2.2.2 Number of Interviews Conducted throughout the Research Process

9.2.2.3 Primary Stakeholders

9.2.2.4 Discussion Guide for Primary Participants

9.2.3        Expert Panels

9.2.3.1 Expert Panels Across 30+ Industry

9.2.4        Paid Local Experts

9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region

9.3   Market Estimation

9.3.1        Top-Down Approach

9.3.1.1 Macro-Economic Indicators Considered

9.3.1.2 Micro-Economic Indicators Considered

9.3.2        Bottom Up Approach

9.3.2.1 Company Share Analysis Approach

9.3.2.2 Estimation of Potential Product Sales

9.4   Data Triangulation

9.4.1        Data Collection

9.4.2        Time Series, Cross Sectional & Panel Data Analysis

9.4.3        Cluster Analysis

9.5   Analysis and Output

9.5.1        Inhouse AI Based Real Time Analytics Tool

9.5.2        Output From Desk & Primary Research

9.6   Research Assumptions & Limitations

9.7.1        Research Assumptions

9.7.2        Research Limitations

LIST OF TABLES

1 Global Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Mllion)

2 Monoclonal Antibody Drugs Market, By Region, 2020-2028 (USD Mllion)              

3 Immunosuppressive Agents Market, By Region, 2020-2028 (USD Mllion)

4 Plasma Exchange Therapy Market, By Region, 2020-2028 (USD Mllion)     

5 Others Market, By Region, 2020-2028 (USD Mllion)

6 Global Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Mllion)       

7 Tablets Market, By Region, 2020-2028 (USD Mllion)              

8 Injections Market, By Region, 2020-2028 (USD Mllion)

9 Others Market, By Region, 2020-2028 (USD Mllion)

10 Global Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Mllion)

11 Hospitals Market, By Region, 2020-2028 (USD Mllion)         

12 Specialty Clinics Market, By Region, 2020-2028 (USD Mllion)         

13 Homecare Market, By Region, 2020-2028 (USD Mllion)        

14 Others Market, By Region, 2020-2028 (USD Mllion)

15 Regional Analysis, 2020-2028 (USD Mllion)

16 North America Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

17 North America Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

18 North America Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

19 North America Neuromyelitis Optica Spectrum Disorder Market, By Country, 2020-2028 (USD Million)

20 U.S Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

21 U.S Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

22 U.S Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

23 Canada Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

24 Canada Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

25 Canada Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

26 Mexico Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

27 Mexico Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

28 Mexico Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

29 Europe Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

30 Europe Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

31 Europe Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

32 Germany Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

33 Germany Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

34 Germany Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

35 UK Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

36 UK Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

37 UK Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

38 France Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

39 France Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

40 France Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

41 Italy Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

42 Italy Neuromyelitis Optica Spectrum Disorder Market, By T Dosage Form Type, 2020-2028 (USD Million)

43 Italy Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

44 Spain Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

45 Spain Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

46 Spain Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

47 Rest Of Europe Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

48 Rest Of Europe Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

49 Rest of Europe Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

50 Asia Pacific Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

51 Asia Pacific Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

52 Asia Pacific Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

53 Asia Pacific Neuromyelitis Optica Spectrum Disorder Market, By Country, 2020-2028 (USD Million)

54 China Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

55 China Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

56 China Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

57 India Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

58 India Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

59 India Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

60 Japan Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

61 Japan Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

62 Japan Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

63 South Korea Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

64 South Korea Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

65 South Korea Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

66 Middle East & Africa Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

67 Middle East & Africa Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

68 Middle East & Africa Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

69 Middle East & Africa Neuromyelitis Optica Spectrum Disorder Market, By Country, 2020-2028 (USD Million)

70 Saudi Arabia Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

71 Saudi Arabia Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

72 Saudi Arabia Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

73 UAE Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

74 UAE Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

75 UAE Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

76 Central & South America Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

77 Central & South America Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

78 Central & South America Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

79 Central & South America Neuromyelitis Optica Spectrum Disorder Market, By Country, 2020-2028 (USD Million)

80 Brazil Neuromyelitis Optica Spectrum Disorder Market, By Treatment, 2020-2028 (USD Million)

81 Brazil Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form, 2020-2028 (USD Million)

82 Brazil Neuromyelitis Optica Spectrum Disorder Market, By End-User, 2020-2028 (USD Million)

83 F. Hoffmann-La Roche Ltd.: Products & Services Offering

84 Mylan N.V.: Products & Services Offering  

85 Teva Pharmaceutical Industries Ltd.: Products & Services Offering       

86 Sanofi (France): Products & Services Offering      

87 Pfizer Inc.: Products & Services Offering  

88 GLAXOSMITHKLINE PLC: Products & Services Offering           

89 Novartis AG : Products & Services Offering             

90 Zydus Cadila: Products & Services Offering            

91 Boehringer Ingelheim International GmbH., Inc: Products & Services Offering

92  Apotex Inc.: Products & Services Offering

93 Other Companies: Products & Services Offering  

LIST OF FIGURES

1 Global Neuromyelitis Optica Spectrum Disorder Market Overview

2 Global Neuromyelitis Optica Spectrum Disorder Market Value From 2020-2028 (USD Mllion)

3 Global Neuromyelitis Optica Spectrum Disorder Market Share, By Treatment (2022)

4 Global Neuromyelitis Optica Spectrum Disorder Market Share, By Dosage Form (2022)

5 Global Neuromyelitis Optica Spectrum Disorder Market Share, By End-User (2022)

6 Global Neuromyelitis Optica Spectrum Disorder Market, By Region (Asia Pacific Market)

7 Technological Trends In Global Neuromyelitis Optica Spectrum Disorder Market

8 Four Quadrant Competitor Positioning Matrix

9 Impact Of Macro & Micro Indicators On The Market

10 Impact Of Key Drivers On The Global Neuromyelitis Optica Spectrum Disorder Market

11 Impact Of Challenges On The Global Neuromyelitis Optica Spectrum Disorder Market

12 Porter’s Five Forces Analysis

13 Global Neuromyelitis Optica Spectrum Disorder Market: By Treatment Scope Key Takeaways

14 Global Neuromyelitis Optica Spectrum Disorder Market, By Treatment Segment: Revenue Growth Analysis

15 Monoclonal Antibody Drugs Market, By Region, 2020-2028 (USD Mllion)

16 Immunosuppressive Agents Market, By Region, 2020-2028 (USD Mllion)

17 Plasma Exchange Therapy Market, By Region, 2020-2028 (USD Mllion)

18 Others Market, By Region, 2020-2028 (USD Mllion)    

19 Global Neuromyelitis Optica Spectrum Disorder Market: By Dosage Form Scope Key Takeaways

20 Global Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form Segment: Revenue Growth Analysis

21 Tablets Market, By Region, 2020-2028 (USD Mllion)  

22 Injections Market, By Region, 2020-2028 (USD Mllion)

23 Others Market, By Region, 2020-2028 (USD Mllion)    

24 Global Neuromyelitis Optica Spectrum Disorder Market: By End-User Scope Key Takeaways

25 Global Neuromyelitis Optica Spectrum Disorder Market, By End-User Segment: Revenue Growth Analysis

26 Hospitals Market, By Region, 2020-2028 (USD Mllion)

27 Specialty Clinics Market, By Region, 2020-2028 (USD Mllion)

28 Homecare Market, By Region, 2020-2028 (USD Mllion)

29 Others Market, By Region, 2020-2028 (USD Mllion)                

30 Regional Segment: Revenue Growth Analysis

31 Global Neuromyelitis Optica Spectrum Disorder Market: Regional Analysis

32 North America Neuromyelitis Optica Spectrum Disorder Market Overview

33 North America Neuromyelitis Optica Spectrum Disorder Market, By Treatment

34 North America Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form

35 North America Neuromyelitis Optica Spectrum Disorder Market, By End-User

36 North America Neuromyelitis Optica Spectrum Disorder Market, By Country

37 U.S. Neuromyelitis Optica Spectrum Disorder Market, By Treatment

38 U.S. Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form

39 U.S. Neuromyelitis Optica Spectrum Disorder Market, By End-User

40 Canada Neuromyelitis Optica Spectrum Disorder Market, By Treatment

41 Canada Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form

42 Canada Neuromyelitis Optica Spectrum Disorder Market, By End-User

43 Mexico Neuromyelitis Optica Spectrum Disorder Market, By Treatment

44 Mexico Neuromyelitis Optica Spectrum Disorder Market, By Dosage Form

45 Mexico Neuromyelitis Optica Spectrum Disorder Market, By End-User

46 Four Quadrant Positioning Matrix

47 Company Market Share Analysis

48 F. Hoffmann-La Roche Ltd.: Company Snapshot

49 F. Hoffmann-La Roche Ltd.: SWOT Analysis

50 F. Hoffmann-La Roche Ltd.: Geographic Presence

51 Mylan N.V.: Company Snapshot

52 Mylan N.V.: SWOT Analysis

53 Mylan N.V.: Geographic Presence

54 Teva Pharmaceutical Industries Ltd.: Company Snapshot

55 Teva Pharmaceutical Industries Ltd.: SWOT Analysis

56 Teva Pharmaceutical Industries Ltd.: Geographic Presence

57 Sanofi (France): Company Snapshot

58 Sanofi (France): Swot Analysis

59 Sanofi (France): Geographic Presence

60 Pfizer Inc.: Company Snapshot

61 Pfizer Inc.: SWOT Analysis

62 Pfizer Inc.: Geographic Presence

63 GLAXOSMITHKLINE PLC: Company Snapshot

64 GLAXOSMITHKLINE PLC: SWOT Analysis

65 GLAXOSMITHKLINE PLC: Geographic Presence

66 Novartis AG : Company Snapshot

67 Novartis AG : SWOT Analysis

68 Novartis AG : Geographic Presence

69 Zydus Cadila: Company Snapshot

70 Zydus Cadila: SWOT Analysis

71 Zydus Cadila: Geographic Presence

72 Boehringer Ingelheim International GmbH., Inc.: Company Snapshot

73 Boehringer Ingelheim International GmbH., Inc.: SWOT Analysis

74 Boehringer Ingelheim International GmbH., Inc.: Geographic Presence

75  Apotex Inc.: Company Snapshot

76  Apotex Inc.: SWOT Analysis

77  Apotex Inc.: Geographic Presence

78 Other Companies: Company Snapshot

79 Other Companies: SWOT Analysis

80 Other Companies: Geographic Presence

The Global Neuromyelitis Optica Spectrum Disorder Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Neuromyelitis Optica Spectrum Disorder Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Neuromyelitis Optica Spectrum disorder market is projected to grow at a CAGR of 6.2% from 2023 to 2028
F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi (France), Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Zydus Cadila, Boehringer Ingelheim International GmbH., Apotex Inc., and AstraZeneca among others, are some of the key players in the global neuromyelitis optica spectrum disorder market.
The increasing incidence and prevalence of neuromyelitis optica spectrum disorder (NMOSD), increasing investment in rare disease treatment infrastructure, and rising demand for better treatment options for neuromyelitis optica spectrum disorder are some of the opportunities prevailing in the market.
The high prevalence of multiple sclerosis (MS), rising demand for innovative drugs including mAbs, and the launch of new products and therapies are expected to support the market in the forecast period.

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Fedex
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Siemens
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - DuPont
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Toray
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - L&T
  • Client of Global Market Estimates - Integralife
  • Client of Global Market Estimates - Synamedia
  • Client of Global Market Estimates - Sorrento Therapeutics
  • Client of Global Market Estimates - Solenis
  • Client of Global Market Estimates - Sartorius